Arcus Biosciences (NYSE:RCUS) used its fourth-quarter and full-year 2025 earnings call to highlight updated clinical data for its lead oncology program, casdatifan, and to outline near-term plans for ...
Globant (NYSE:GLOB) executives used the company’s fourth-quarter 2025 earnings call to outline what they described as a shift ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results